Imagine treating a brain tumor by shining a specific light that kills cancer cells without needing to inject any toxic dyes first. Current methods are like trying to paint a room but only reaching the corners; this new light reaches the hidden, scattered cells. It uses a special wavelength of light to trigger a natural reaction that destroys the tumor from the inside.
Glioma is lethal because cancer cells diffuse deep into the brain where they cannot be safely removed. Current light therapies require expensive, toxic chemicals (photosensitisers) that cannot reach these distant cells effectively.
Developed 1267nm Continuous Wave and Ultra Short Pulse laser prototypes and a preclinical delivery and sensing system (pcGlio-DSS).
If you are a laser manufacturer dealing with the limitations of traditional photodynamic therapy — this project developed 1267nm ultra short pulse laser systems that eliminate the need for expensive photosensitisers. This allows for the creation of a new class of medical devices for deep-tissue oncology.
If you are a pharma company dealing with the toxicity and cost of photosensitizers in cancer treatment — this project developed Direct Light Therapy (DLT) which generates reactive oxygen species without chemical additives. This removes the need for developing and administering toxic PS agents.
If you are a clinic dealing with the high recurrence of glioma due to diffuse cells — this project developed the pcGlio-DSS delivery and sensing system. This tool enables the treatment of deeply embedded cells that are currently too risky to remove surgically.
Based on available project data, the technology removes the dependency on expensive and potentially toxic photosensitisers, which reduces the overall cost and complexity of the treatment process.
Based on available project data, the project is currently developing prototypes of ultra short pulse laser systems and a preclinical delivery system, meaning it is in the prototype stage rather than industrial scale.
The provided data does not specify patent numbers or licensing terms, but it confirms the successful production of Continuous Wave 1267nm laser systems.
The project runs from 2024-01-01 to 2026-12-31, focusing on preclinical delivery and sensing systems to prepare for future clinical translation.
The project is developing the pcGlio-DSS (preclinical GlioLighT delivery and sensing system) to ensure the light therapy can be delivered and monitored effectively within the brain.
The consortium consists of 8 partners across 5 countries, showing a strong academic lean with 4 universities and 2 research institutes. With an industry ratio of 12% (1 company) and 2 SMEs, the project is heavily focused on the R&D and validation phase, though the inclusion of SMEs suggests a path toward commercialization of the laser hardware.
Contact the research office at Johannes Gutenberg-Universität Mainz
Contact us to identify licensing opportunities for the 1267nm USP laser technology.
